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SUMMARY. Vaccination against hepatitis B virus (HBV)
immediatelyafterbirthpreventsneonatalinfectionbyvertical
transmission from HBV carrier mothers. There is an ongoing
debate whether infant vaccination is sufﬁcient to protect
against infection when exposed to HBV later in life. We
studied 222 Thai infants born to HBsAg )/+ and HBeAg )/+
mothers who were vaccinated with recombinant hepatitis B
vaccine at 0-1-2-12 months of age. A subset of 100 subjects
receivedaboosterdoseatage5 years.Bloodsamplescollected
yearly for 20 years were examined for anti-HBs antibodies
and serological markers of hepatitis B infection (anti-HBc,
HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA).
During the 20-year follow-up, no subject acquired new
chronic HBV infection or clinical hepatitis B disease. During
the ﬁrst decade, possible subclinical breakthrough HBV
infection (anti-HBc seroconversion) was only observed in
subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]).
During the second decade, breakthrough HBV infections
were detected in all groups (18/140 [12.8%]). Increases in
anti-HBs concentrations that were unrelated to additional
HBV vaccination or infection were detected in approximately
10% of subjects in each decade. Primary infant vaccination
with a recombinant hepatitis B vaccine confers long-term
protectionagainstclinicaldiseaseandnewchronichepatitisB
infection despite conﬁrmed hepatitis B exposure. (http://
www.clinicaltrials.gov NCT00240500 and NCT00456625)
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INTRODUCTION
Hepatitis B remains a serious global public health problem
despite the availability of effective vaccines for several dec-
ades. It is estimated that two billion individuals have been
infected with hepatitis B virus (HBV) worldwide and
360 million individuals have chronic HBV infection and are
at risk of death because of liver cirrhosis and hepatocellular
carcinoma [1].
Chronic HBV is the most likely outcome when infection is
acquired perinatally [1]. If a mother is positive for both HBV
surface antigen (HBsAg) and HBV e antigen (HBeAg), the
risk of chronic infection is as high as 70–90%. Thus, pre-
vention of infection at an early age is critical in preventing
chronic carriage and subsequent morbidity and mortality
associated with chronically evolving infection. Infant
immunization against HBV has been recommended by the
World Health Organization since 1988 [2].
Countries in South-East Asia have historically been regions
of high HBV endemicity [3–5]. However, infant vaccination
has been highly successful in preventing HBV infection and
sequelae, including deaths because of fulminant hepatitis
and hepatocellular carcinoma, in countries where it has
been implemented [6–9]. In Thailand, nationwide infant
vaccination against HBV began in 1992. At that time, the
incidence of HBV carriage was ashigh as 12% in some groups
[5]. Twelve years after onset of nationwide immunization,
HBsAg seroprevalence in vaccinated 6 month to 18-year-
olds had dropped from 4.3% to 0.7% [7]. This reduction
has been maintained, with anti-HBc seroprevalence also
decreasing from 15.8% to 2.9% [7]. The risk of hepatocellular
carcinoma is signiﬁcantly lower in HBV-vaccinated children
in Thailand, than in unvaccinated children [10].
The success of infant vaccination programmes in pre-
venting vertical transmission of HBV during infancy and
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about long-term protection following infant vaccination in
high endemicity countries. The development of clinical or
chronic hepatitis B after completion of primary vaccination
in infancy has not been described [11]. However, most fol-
low-up studies of vaccinated cohorts rely on isolated sero-
logical snapshots taken many years apart to identify
exposure or infection. In a serological follow-up study of
infants from Thailand, a high endemicity region of South-
East Asia, who were vaccinated against HBV in infancy, we
assessed serological parameters of HBV infection yearly for
20 years. This study provides a dynamic description of
serological proﬁles in vaccinated subjects over time.
MATERIALS AND METHODS
Subjects and study design
The initial primary vaccination study was open labelled,
with three groups based on the HBV infectious status of
the mothers (HBsAg +/) and HBeAg +/)) and has been
published previously [12,13]. Infants were vaccinated with
recombinant hepatitis B vaccine (10 lg recombinant
HBsAg; Engerix
TM-B; GlaxoSmithKline Biologicals, Rixensart,
Belgium) according to a 0-, 1-, 2- and 12-month schedule,
beginning at birth. At 5 years of age, 100 subjects received
a booster dose of the same vaccine [14]. Details of study
groups and basis for their classiﬁcation are presented in
Fig. 1. The study was conducted between 1986 and 1988 at
the Chulalongkorn University Hospital, Bangkok, Thailand.
All subjects were invited to attend yearly follow-up visits
for 20 years (excluding Year 11 and Year 16 when no blood
sampling was performed because of administrative delays in
protocol development and approval) (study 100448, http://
www.clinicaltrials.gov NCT00240500). At each visit, sub-
jects were questioned about HBV clinical symptoms, and a
blood sample was drawn. Informed consent was obtained
from subjects before initiation of study procedures.
At Year 20, subjects who had anti-HBs below 100 mIU/
mL at the previous follow-up were invited to participate in a
challenge study in which they were given an additional dose
of hepatitis B vaccine (Engerix
tm-B, containing 10 lg HBsAg)
to assess immune memory following exposure. Results of the
long-term follow-up until Year 8 have been reported previ-
ously [14,15]. Humoral and cellular immune responses until
Years 18–20 have been reported elsewhere [16]. Full
immunological follow-up until Year 20 and response to the
additional HBV dose have been reported in [17].
The studies were approved by the Institutional Ethic
Committees, Faculty of Medicine, Chulalongkorn University
and were conducted according to Good Clinical Practice, the
Declaration of Helsinki (1996) and local rules and regula-
tions of Thailand.
Assessment of immunogenicity
All blood samples were tested for anti-HBs, HBsAg and anti-
HBc. Between Year 12 and Year 15, a subset of selected
samples in which HBsAg and/or anti-HBc was detected were
tested for HBV DNA by polymerase chain reactions (PCR).
During the ﬁnal 4 years of follow-up, all serum samples
positive for HBsAg and/or anti-HBc were further tested for
HBV DNA, HBeAg and anti-HBe to further characterize the
putative HBV infection. HBV DNA (core-pre-core-region)
was measured using the COBAS Amplicor HBV Monitor
(Roche Molecular Systems Inc., Branchburg, NJ, USA), [18],
Fig. 1 Study design.
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developed in house (ampliﬁcation of 400 bp region using the
primers: HBV-Fw 5¢-TTATCGCTGGATGTGTCTGC-3¢ and
HBV-Rv 5¢-CAGACTTGGCCCCCAATACC-3¢). Liver enzymes
were also measured during the ﬁnal 4 years of follow-up, to
evaluate clinical signiﬁcance of breakthrough infection.
During the 20-year follow-up, some assays were replaced
based on commercial availability and as new technologies
became available. A list of the laboratory methods used over
the duration of the study is given in Table 1.
Statistical methods
The clinical signiﬁcance of HBsAg-positive and/or anti-HBc-
positive samples was reviewed for each subject, taking into
account: the presence of other HBV markers (anti-HBs,
HBeAg, anti-HBe); the presence of HBV DNA (pre-core/core
and surface antigen); serum transaminase activities (ALT/
AST) together with the medical history of the subject and the
presence of HBV markers at previous or subsequent time
points. Based on these results, subjects were classiﬁed
according to the following criteria:
• Chronic HBV infection: HBsAg+ AND anti-HBc+ at more
than two consecutive time points;
• Clinical HBV infection: Clinical, serologically conﬁrmed
HBV infection;
• False positive: Single marker of HBV infection (HBsAg,
PCR, HBeAg, anti-HBc) positive in one sample, AND all
other markers negative in this sample, AND this and
other HBV markers negative at consecutive time points;
• Possible subclinical breakthrough HBV infection: One or
more HBV marker positive in one or more consecutive
samples, excluding conditions for chronic HBV infection
and false positive result, without any reported clinical
symptoms of hepatitis;
• Isolated natural booster: ‡Fourfold increase in anti-HBs
concentrations if <100 mIU/mL at previous time point,
OR ‡twofold increase in anti-HBs concentrations if
‡100 mIU/mL at previous time point, AND all other
serological markers for HBV infection negative at this
time point.
This classiﬁcation was performed separately for the ﬁrst
and the second decades. A subject was considered evaluable
if results were available for at least two blood samples in a
given decade. Subjects that acquired chronically evolving
HBV infection in the perinatal period (n = 2) were excluded
from further analysis.
RESULTS
Study population
Two hundred and twenty-two infants were enrolled at the
study onset, which was initiated in 1986. Of these, 109
subjects participated in the ﬁnal follow-up visit 20 years
later. At Year 20, the mean age of the subjects was
19.6 ± 0.49 years, and 49.5% of subjects were men. All
subjects were of Asian or South-East Asian heritage.
Incidence of HBV infectious events over time
Perinatal HBV infection that evolved towards chronicity was
acquired at birth by two subjects who did not respond to the
primary vaccination course. These subjects were described
Table 1 Laboratory assays
Marker Assay Time point Method Test Kit/Manufacturer Assay cut-off
Anti-HBs Y0–Y13 RIA AUSAB/Abott 1 mIU/mL
Y14–Y18 EIA AUSAB/Abbott 3.3 mIU/mL
Y19–Y20 EIA In house 3.3 mIU/mL
Anti-HBc Y0–Y13 RIA Corab/Abbott +/)
Y14–Y20 EIA AxSYM CORE/Abbott +/)
HBsAg Y0–Y12 RIA AusRIA/Abbott +/)
Y13–Y20 EIA AxSYM HBsAg/Abbott. +/)
Anti-HBe Y16–Y20 EIA AxSYM/Abbott +/)
HBeAg Y16–Y20 EIA AxSYM/Abbott +/)
HBV DNA (HBsAg) Y12–Y15 subset PCR In house +/)
Y16–Y20 PCR In house +/)
HBV-DNA (HBsAg) Y16–Y20 Sequencing NA NA
HBV DNA (Pre-core/core) Y17 PCR Cobas monitor/Roche 200 copies/mL
Y18–Y20 PCR Cobas monitor/Roche 316 copies/mL
AST Y16–Y20 Kinetic UV assay Roche Diagnostics 0–38 U/L
ALT Y16–Y20 Kinetic UV assay Roche Diagnostics 0–38 U/L
Y, year of follow-up; EIA, Enzyme-linked immunoassay; NA, not applicable; mIU/mL, milli International Units per millilitre;
U/L, units per litre.
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Protection against hepatitis B after 20 years 371previously [13]. During the 20-year follow-up, none of the
remaining subjects acquired a HBV infection that evolved
chronically (determined by the observation of HBsAg and
anti-HBc seropositivity for more than two consecutive time
points) (Table 2). None of the subjects reported clinical
symptoms of HBV disease during the 20-year follow-up.
None showed elevated ALT or AST during the study.
During the ﬁrst decade, possible subclinical breakthrough
HBV infections, accompanied by the emergence of anti-HBc
antibodies, were only observed in subjects born to mothers
positive for both HBsAg and HBeAg (2/21 [9.5%] in group 1
and 4/28 [14.3%] in group 2).
During the second decade, possible subclinical break-
through HBV infections were detected in all groups: 4/18
(22.2%) in group 1, 6/21 (28.6%) in group 2, 4/41 (9.8%)
in group 3, 2/32 (6.3%) in group 4, 1/22 (4.5%) in group 5
and 1/6 (16.7%) in group 6.
Increases in anti-HBs concentrations, unrelated to addi-
tional HBV vaccination or HBV infection, were detected in
10% of subjects in the ﬁrst decade and 10.7% in the second
decade. If not related to vaccine administration, these are
likely to have been caused by natural boosting.
False positive results (according to the deﬁnition men-
tioned earlier) were detected in 23 subjects. In most cases,
this was an isolated HBsAg+ result that was most frequently
observed with the AxSYM HBsAg (Abbott) assay used in the
ﬁnal years of the follow-up (Y13–Y20). All of the HBsAg
results in these subjects were low values ranging between
2.02 and 3.63 (assay cut-off for positive >2 S/N ratio),
suggesting these were indeed false positive results.
Longitudinal assessment of possible breakthrough cases
Twenty-four subjects with possible subclinical HBV break-
through infections were identiﬁed. Individual analysis of
serological results allowed further differentiation of these
subjects into three subgroups showing different serological
proﬁles:
Eleven subjects seroconverted for anti-HBc antibodies
during the follow-up period and showed an anti-HBs booster
response compatible with a self-limited breakthrough infec-
tion. An example of such a serological proﬁle is provided in
Fig. 2a. Interestingly, one of these subjects was a low
responder to primary vaccination and the 12-month booster
dose (<100 mIU/mL). This subject had undetectable anti-
HBs antibodies from Year 13 onwards. However, upon
exposure to the virus at 17 years of age, as indicated by
emergence of anti-HBc antibodies, anti-HBs antibodies rose
sharply (Fig. 2b).
Three subjects developed detectable antibodies against
HBc during the follow-up period but showed no indication of
an anti-HBs booster response (Fig. 2c).These three subjects
Table 2 Incidence of hepatitis B infectious events
Assessment per subject
Mother
HBsAg+ HBeAg+
Mother
HBsAg+ HBeAg)
Mother
HBsAg) HBeAg)
Decade 1 Decade 2 Decade 1 Decade 2 Decade 1 Decade 2
Boosted at age 5 Group
N =2 1
n (%)
N =1 8
n (%) Group
N =4 5
n (%)
N =4 8
n (%) Group
N =3 3
n (%)
N =2 2
n (%)
False positive 1 0 (0.0) 2 (11.1) 3 0 (0.0) 4 (9.8) 5 1 (3.0) 2 (9.1)
Isolated natural
booster response
3 (14.3) 5 (27.8) 2 (4.4) 4 (9.8) 1 (3.0) 3 (13.6)
Subclinical breakthrough
HBV infection
2 (9.5) 4 (22.2) 0 (0.0) 4 (9.8) 0 (0.0) 1 (4.5)
Clinical HBV infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
New chronic HBV infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unboosted Group
N =2 8
n (%)
N =2 1
n (%) Group
N =4 3
n (%)
N =3 2
n (%) Group
N =1 0
n (%)
N =6
n (%)
False positive 2 2 (7.1) 2 (9.5) 4 0 (0.0) 9 (28.1) 6 0 (0.0) 1 (16.7)
Isolated natural
booster response
5 (17.9) 1 (4.8) 6 (14.0) 1 (3.1) 1 (10.0) 1 (16.7)
Subclinical breakthrough
HBV infection
4 (14.3) 6 (28.6) 0 (0.0) 2 (6.3) 0 (0.0) 1 (16.7)
Clinical HBV infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
New chronic HBV infection 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
N, Number of evaluable subjects/group/decade; Note Group 6, 2nd decade N = 6, thus results should be interpreted cautiously.
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anti-HBs concentration of 1096–6575 mIU/mL), and the
detection of anti-HBc antibodies at multiple time points is a
clear indication for exposure to the virus.
Finally, 10 subjects had more than one positive serological
marker for HBV infection, or the same marker was detected
at more than one time point. In these 10 subjects, neither an
anti-HBs booster response, nor emergence of anti-HBc anti-
bodies was observed after the apparent infection. This type of
serological proﬁle is illustrated in Fig. 2d. Isolated positive
HBsAg samples were found in all these subjects, ﬁve had
HBV DNA detected with values between 2730 and
10 730 copies/mL. One subject was also positive for HBeAg
on one occasion.
DISCUSSION
Long-term serological follow-up studies after hepatitis B
vaccination frequently assess the serostatus of individuals at
infrequent, widely spaced intervals. These serological snap-
shots may be subject to confounding factors including
detection of false positives. This longitudinal study spanning
20 years provides a unique, dynamic view of the evolving
serological status of subjects over time. This study shows the
efﬁciency of infant HBV vaccination in preventing HBV
infection, as well as the serological consequences of HBV
exposure/infection for two decades after vaccination.
In total, 24/109 subjects (22%) showed strong serological
evidence of exposure to HBV over the 20-year follow-up
period. During the ﬁrst decade, serological indications of
transient asymptomatic HBV infections were only observed
in subjects born to high risk families (mother positive for
both HBsAg and HBeAg, groups 1 and 2). This is consistent
with the notion that at a very young age, HBV infection is
mostly transmitted through household contact. In the sec-
ond decade, breakthrough infections were detected in 12.9%
of subjects and occurred in all groups, possibly reﬂecting
increased exposure outside the home linked to adolescent
risk behaviours. In addition, isolated increases in anti-HBs
antibody concentrations, indicative of natural boosting
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Fig. 2 (a) Subject who seroconverted for antibodies against HBc during the follow-up period, with anti-HBs booster response.
(b) Subject (not boosted at Year 5) with >1 serological marker indicative of hepatitis B infection, unaccompanied by anti-HBs
booster response or emergence of antibodies to HBc. (c) Subject who developed detectable antibodies against HBc during the
follow-up period without an anti-HBs booster response. (d) Response to possible subclinical breakthrough HBV infection in a
low responder after primary and booster vaccination (no booster given at Year 5). In all graphs, the response to adminis-
tration of a challenge dose of HBV vaccine at Year 20 is evident.
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Protection against hepatitis B after 20 years 373caused by exposure to HBV, were observed in approximately
10% of subjects in all groups each decade. This level of
exposure is compatible with epidemiological data for HBV in
Thailand; in a seroprevalence study, anti-HBc seropreva-
lence in (unvaccinated) 18- to 20-year-old Thai subjects
was 21.7% [7]. Despite this high risk of exposure to HBV,
none of the subjects acquired chronic HBV infection nor did
any subject report clinical symptoms of HBV disease. These
results therefore suggest that infant HBV vaccination
protects against clinical hepatitis B disease and chronic
carriage until at least 20 years of age.
Of the 24 individuals with evidence of possible subclinical
breakthrough HBV infection (occult infection), 11 showed a
typical response with emergence of anti-HBc antibodies and
an anti-HBs booster response. Notably one subject had a low
response to the primary vaccination course but still retained
immunological memory to the virus 17 years later.
Atypical proﬁles were observed in 13 subjects. All three
anti-HBc seroconverters without an anti-HBs booster
response showed good anti-HBs responses to the primary
vaccination course, as well as a response to a challenge dose
administered 20 years later (Fig. 2c, other data not shown).
The latter suggests that immune memory to the vaccine
antigen was still present in these subjects and prevented
HBsAg expression during the HBV infection to reach levels
capable of boosting anti-HBs responses. In two of these
subjects, HBV was also detected with PCR and/or HBsAg
ELISA, making it unlikely that the anti-HBc conversion was
aspeciﬁc. For neither of these subjects was the viral DNA
successfully sequenced, making it impossible to ascertain
whether these infections were attributed to mutated forms of
the virus, of which the HBsAg was not recognized by the
immune system. Importantly none of these subjects reported
clinical signs of disease nor was an increase in liver enzymes
detected.
Finally, the clinical interpretation of results from 10 sub-
jects who were positive for HBsAg on one or more occasion
or had other serological signs of HBV infection without
developing detectable antibodies against HBc is less clear. An
atypical presentation of breakthrough infection cannot be
excluded; however, sample contamination or false positive
results may also be responsible for these ﬁndings.
Previous follow-up studies in countries of high HBV
endemicity have shown good protection against HBV car-
riage following infant vaccination with both plasma-derived
and recombinant vaccines [19–22]. However, the impor-
tance of natural boosters in maintaining immunity, and the
response of subjects on exposure to HBV, is not well
described. In this study, the serological consequences of HBV
exposure have been documented, and the ability of vacci-
nated subjects to clear HBV after subclinical infection has
been demonstrated. These results are in line with those of
a longitudinal study conducted in China in which yearly
blood samples were collected from individuals vaccinated in
infancy with either plasma derived or recombinant vaccines
[23]. During the 22 years of the study, 23% had an anti-HBs
booster response during the 22 years of the study, and no
hepatitis B cases with evolving chronicity were documented
[23]. Serological results that were not easily explained were
also observed, with a small percentage of subjects becoming
anti-HBc positive during the study without increase in anti-
HBs.
In conclusion, primary infant vaccination with a
recombinant HBV vaccine confers long-term protection
against clinical disease and HBV infections that evolve
towards chronicity, despite conﬁrmed HBV exposure. Break-
through infections became more frequent in the second
decade of life, suggesting an increase in exposure and self-
limiting infection with hepatitis B.
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